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The serine anti-protease elafin is 
expressed by monocytes, alveolar 
macrophages, neutrophils and at 
mucosal surfaces, and possesses 
antimicrobial activity. It is also known 
to reduce lipopolysaccharide (LPS)-
induced neutrophil influx into murine 
alveoli as well as abrogating LPS-
induced production of MMP-9, MIP-2 
and TNF-α by as yet unidentified 
mechanisms. In this report we have 
shown that elafin inhibits the LPS-
induced production of MCP-1 in 
monocytes by inhibiting AP-1 and NF-
κB activation. Elafin prevented LPS-
induced  phosphorylation of  ATF2, c-
jun and JNK, but had no effect on LPS-
induced phosphorylation of p38. The 
LPS-induced degradation of IRAK, 
IκBα and IκBβ was inhibited by elafin, 
but phosphorylation of IκBα was 
unaffected. Polyubiquitinated protein 
was shown to accumulate in the 
presence of elafin. These results suggest 
that elafin’s inhibition of LPS-induced 
AP-1 and  NF-κB  activation occurs via 
an effect on the ubiquitin-proteasome 
pathway.  
 
 
 
        Elafin is a 6 kilodalton serine anti-
protease initially identified in psoriatic 
skin scales, and also called skin-derived 
anti-leucoprotease (SKALP). 
Subsequently, “elastase-specific inhibitor” 
was isolated from human sputum, and 
found to have identical N-terminal 
sequencing as SKALP, and the term elafin  
 
 
 
 
 
was suggested (1). Elafin is currently  
known to be expressed in airways, other 
mucosal surfaces such as oesophagus, 
vagina, endometrium, coronary intima, 
and by inflammatory cells such as 
monocytes, alveolar macrophages and 
neutrophils. 
 
     Structurally, elafin is a member of the 
WAP (whey acidic protein) family of 
proteins characterised by possessing a C-
terminal core domain consisting of 4 
disulphide bonds. Also known as trappins 
(TRansglutaminase substrate and wAP 
domain containing ProteIN), these 
proteins also possess an N-terminal 
domain consisting of a variable number of 
repeats with the consensus sequence Gly-
Gln-Asp-Pro-Val-Lys that can act as an 
anchoring motif by transglutaminase 
cross-linking (2). Pre-elafin, also known 
as trappin 2, is thought to undergo 
proteolytic cleavage, possibly by tryptase, 
releasing the elafin molecule (3). Elafin is 
a cationic protease inhibitor of human 
neutrophil elastase (HNE), proteinase 3 
and porcine pancreatic elastase, and is 
induced by cytokine and other stimuli 
including IL-1β, TNF, HNE and 
lipopolysaccharide (LPS) (1). The gene 
governing elafin (and other WAP proteins) 
expression was cloned and sequenced on 
the long arm of chromosome 20. 
Transcriptional activation of elafin appears 
to be cell-specific; in pulmonary epithelial 
cells elafin is regulated at a transcriptional 
level by the transcription factor nuclear 
factor kappa B (NF-κB) (4) while in 
mammary epithelial cells the transcription  
 
 
 
 
 
 
factor activating protein-1 (AP-1) 
mediates transcriptional activation (5).  
  
    The observation that elafin is highly 
cationic and shows selective expression at 
mucosal, epithelial and endothelial 
surfaces suggested that it possesses 
antimicrobial properties. Indeed, elafin has 
been shown to have antimicrobial activity 
which is independent of it’s anti-elastase 
activity or charge properties (6). In mice, 
pre-elafin has been shown to dose-
dependently reduce LPS-induced 
neutrophil influx into alveoli, in addition 
to inhibiting LPS-induced production of  
the potent neutrophil attractants MMP-9 
(gelatinase) and MIP-2 (macrophage 
inflammatory protein-2), suggesting an        
immunomodulatory role in innate 
immunity (7). We have previously shown 
that secretory leucoprotease inhibitor 
(SLPI), another WAP  protein closely 
related to elafin, prevents 
lipopolysaccharide-induced IκBα 
degradation without affecting 
phosphorylation or ubiquitination in 
monocytic cells (8), and furthermore, that 
SLPI can also impair lipotechoic acid 
(LTA)-induced proinflammatory gene 
expression in monocytes and macrophages 
in vitro, processes diminished by oxidation 
and elastase complex formation of SLPI 
(9). 
    
    In light of these results, we have looked 
at the modulatory effects of elafin on LPS 
signalling in U937 cells, including elafin’s 
effect on LPS-induced monocyte 
chemotactic protein-1 (MCP-1). MCP-1 is 
a CC chemokine produced by 
mononuclear phagocytes and is a potent 
activator of monocyte function (10,11). 
MCP-1 has a crucial role in monocyte 
recruitment in vivo in several organs and 
tissues (12-14) and it’s role in monocyte 
infiltration in several inflammatory 
diseases has been described (10,11). MCP-
1 gene expression is cell-type and 
stimulus-specific, and it’s transcription is 
regulated by transcription factors 
including AP-1 and NF-κB (15-18). In 
addition, LPS-induced MCP-1 expression 
has been shown to be dependent on c-jun 
NH2-terminal kinase (JNK) activation 
(19). In this report we show that elafin 
inhibits the LPS-induced production of 
MCP-1 in U937 cells via inhibition of AP-
1 and NF-κB, and that this occurs through 
elafin’s effect upon the ubiquitin-
proteasome pathway. 
 
 
Experimental Procedures 
 
 
  Materials-- RPMI 1640 medium was 
obtained from GIBCO, and U937 cells 
were purchased from the American Type 
Culture Collection (Manassas, VA). 
Recombinant human Elafin was obtained 
from Proteo Biotech AG (Kiel, Germany). 
Antibodies to phosphorylated and total 
ATF2, c-jun, JNK and IκBα, and to 
IRAK, IκBβ and phosphorylated p38 were 
obtained from Cell Signaling Technology 
(Beverly, MA). Antibody to p38 and lamin 
B1 was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). IRAK-1 
antibody was obtained from BD 
Biosciences (San Jose, CA). Antibody to 
ubiquitin was purchased from Sigma.  
Western blotting reagents were obtained 
from Pierce Biotechnology (Rockford, IL). 
Fluorogenic substrates for 20 S 
proteasome activity assays were purchased 
from Merck Biosciences (Nottingham, 
UK).  
Cell Culture-- Human myelomonocytic 
U937 cells were cultured in RPMI 
1640 containing 10% fetal calf serum, 
2 mM glutamine, penicillin, and 
streptomycin and were maintained at 
37 °C in a humidified atmosphere of 5% 
CO2.  
Preparation of Cytoplasmic and Nuclear 
Extracts— After treating cells with elafin 
and/or LPS for the indicated times in 24-
well plates (1 x 106 cells/ml), the cells 
were washed in ice-cold phosphate-
buffered saline and resuspended in a 
hypotonic buffer (10mM HEPES, pH 7.9, 
1.5nM MgCl2, 10mM KCl, and 0.5 mM 
DTT). Cells were  pelletted by 
centrifugation at 14000 x g for 10 min at 
4°C and then lysed for 10 min on ice in 
20µl of hypotonic buffer containing 0.1% 
Igepal CA-630, 1mM sodium vanadate, 
50mM β-glycerophosphate and 1 x 
complete protease inhibitor mixture 
(Roche Molecular Biochemicals). Lysates 
were centrifuged as before, and the 
supernatant (cytoplasmic fraction) was 
retained for Western analysis (see below). 
The remaining nuclear pellet was lysed in 
15µl of lysis buffer (20mM HEPES, pH 
7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 
mM EDTA, 25% (v/v) glycerol, 0.5 mM 
phenylmethylsulfonyl fluoride, 1mM 
sodium vanadate, 50mM β-
glycerophosphate and 1 x complete 
protease inhibitor mixture) for 15 min on 
ice. After centrifugation at 14,000 × g for 
15 min at 4 °C, nuclear extracts were 
removed, and the extracts were stored at 
80 °C. 
EMSA—Nuclear extracts (5 µg) were 
incubated with biotin end-labeled double-
stranded oligonucleotide containing the 
AP-1 or NF-κB consensus sequences 
(MWG Biotech, Germany). Incubations 
were performed for 30 min at room 
temperature in binding buffer (4% (v/v) 
glycerol, 1 mM EDTA, 10 mM Tris-HCl, 
pH 7.5, 100 mM NaCl, 5 mM DTT, 
0.1 mg/ml nuclease-free bovine serum 
albumin) and 2 µg of poly(dI·dC) (Sigma). 
Reaction mixtures were electrophoresed 
on native 6% polyacrylamide gels and 
blotted. Transferred nuclear proteins were 
cross-linked by UV transillumination, 
blocked, incubated with streptavidin 
peroxidase and finally developed by 
chemiluminescent methodology (Pierce 
Biotechnology, Rockford, IL). 
Immunochemical Detection of Proteins-- 
After treating cells with the indicated 
reagents for the indicated times 
cytoplasmic extracts were prepared as 
shown above. Protein concentration of the 
extracts was determined using the 
Bradford method (20). Equal amounts of 
protein from each sample (20 µg for each 
of phosphorylated ATF2 and 
phosphorylated c-jun, and 40 µg for each 
of phosphorylated JNK, phosphorylated 
p38, IRAK, IκBα, IκBβ, phosphorylated 
IκBα and ubiquitin) were electrophoresed 
by SDS-PAGE and blotted. Transferred 
proteins were blocked in 5% dried 
skimmed milk and 1% bovine serum 
albumin in PBST for all proteins except 
phosphorylated JNK, where 5% bovine 
serum albumin in PBST was used. 
Proteins were detected using primary 
antibodies directed against total and 
phosphorylated ATF2, c-jun, JNK, 
phosphorylated p38, IκBα, IκBβ and 
phosphorylated IκBα (1:1000), p38, lamin 
B1, IRAK,  and ubiquitin (1:200) and 
phosphorylated p38 (1:1000)  followed by 
incubation with horse radish peroxidase 
(HRP)-conjugated secondary antibodies 
(1:2000). Antigen-antibody complexes 
were detected with enhanced 
chemiluminescence reagents (Pierce 
Biotechnology, Rockford, IL). 
20 S Proteasome Activity Assays- Three 
different peptidase activities associated 
with the 20 S proteasome were measured 
using the fluorogenic substrates Suc-Leu-
Leu-Val-Tyr-AMC (for chymotrypsin-like 
activity), Z-Leu-Leu-Glu-AMC (for 
peptidylglutamyl peptide hydolyzing 
activity), and Z-Ala-Arg-Arg-AMC (for 
trypsin-like activity). Treated cells were 
lysed in 700 µL of 25mM HEPES, 5mM 
EDTA, 0.1% CHAPS, 5mM ATP, pH 7.5, 
with 2mM DTT (21). Each sample was  
incubated with each substrate (50 µM, 
final concentration) in lysis buffer for 30 
mins at 37 °C, and fluorescence (substrate 
turnover) was determined by excitation at 
355 nm and emission at 460 nm. 
RESULTS 
U937 cells were incubated with LPS for 
24 h following time course and dose-
response experiments (data not shown), 
and some samples were preincubated with 
elafin (10µg/ml) for 1 h followed by 
incubation with LPS. LPS was found to 
induce significantly more MCP-1 
production in U937 cells compared to cells 
incubated in medium alone. Elafin 
inhibited LPS-induced MCP-1 production 
(Fig. 1A). Elafin incubation alone did not 
alter basal MCP-1 levels. These 
experiments were repeated three times 
with similar results.  
  Because MCP-1 expression is regulated 
by the transcription factors, AP-1 and NF-
κB, the effect of elafin on LPS-induced 
transcription factor activation was 
examined by pre-incubating U937 cells 
with elafin (1 h) followed by LPS over the 
time courses shown (Fig. 1B and 1C). LPS 
was shown to induce significantly more 
AP-1 activation in U937 cells (Fig. 1B, 
left, lanes 30, 60 and 120) compared to 
cells incubated in medium alone (Fig. 1B, 
left, lane Con). Elafin prevented LPS-
induced AP-1 activation across the time 
course (Fig. 1B, right). Similarly, LPS 
induced significantly more NF-κB 
activation (Fig. 1C, left, lanes 15, 30 and 
60) versus control (Fig. 1C, lane Con), 
which was markedly inhibited by elafin 
(Fig. 1C, right).                
   To investigate the effect of elafin on 
LPS-induced phosphorylation of AP-1 
subunits, phosphorylation of activating 
transcription factor 2 (ATF2) and c-jun 
was assessed. LPS was shown to induce 
phosphorylation of ATF2 (Fig. 2A, top 
panel, left), and this phosphorylation was 
significantly abrogated by pre-incubation 
with elafin (Fig. 2A, upper panel, right). 
Protein loading was controlled for by 
probing the stripped blot for total ATF2 
(Fig. 2B, lower panel). Similarly, LPS-
induced phosphorylation of c-jun was 
prevented by pre-incubation with elafin 
(Fig. 2B, upper panel). Again, protein 
loading was controlled for by stripping the 
blot and reprobing for total c-jun (Fig. 2B, 
lower panel). 
   ATF2 and c-jun are activated by kinases 
including the mitogen-activated protein 
(MAP) kinases p38 and JNK respectively. 
To assess the effect of elafin on LPS-
induced phosphorylation of p38, cells 
were again either incubated with LPS 
alone or pre-incubated with elafin 
followed by LPS in a time course 
experiment. Equal amounts of cytoplasmic 
extract were electrophoresed, blotted and 
incubated with anti-phosphorylated p38. 
Elafin had no effect on the LPS-induced 
phosphorylation of p38 (Fig. 3A, upper 
panel). To confirm this lack of an effect, 
the stripped blots were reprobed for total 
p38, which showed equal loading (Fig. 
3A, lower panel). Nuclear extracts from 
the same experiments were similarly 
probed for phosphorylated and total p38, 
and again, elafin was shown to have no 
effect on the LPS-induced phosphorylation 
of p38 (Fig. 3B). In order to investigate 
the effect of elafin on LPS-induced 
phosphorylation of JNK, U937s were 
either incubated with LPS or pre-
incubated with elafin followed by LPS 
over a time course of 0, 15, 30, 60 and 120 
min. Elafin prevented the LPS-induced 
phosphorylation of JNK in cytoplasmic  
extracts analyzed by Western blot (Fig. 
3C, upper panel), with protein loading 
controlled for by reprobing the stripped 
blots for total JNK (Fig. 3C, lower panel). 
Similarly, the nuclear extracts from these 
experiments were subjected to Western 
analysis and again, elafin prevented the 
LPS-induced phosphorylation of JNK, 
with lamin B1 shown as a loading control 
(Fig. 3D). 
   To assess the effect of elafin on NF-κB 
regulatory proteins, degradation of IL-1R-
associated kinase (IRAK), IκBα and IκBβ 
were assessed. U937 cells were again 
either incubated with medium alone, with 
LPS or pre-incubated with elafin followed 
by LPS over the time courses shown (Fig. 
4). Western blot analyses of cytoplasmic 
extracts showed LPS-induced degradation 
of IκBα, IκBβ and IRAK (Fig. 4 A-C, left 
rows), whereas preincubation with elafin 
resulted in inhibition of the degradation of 
these proteins (Fig. 4 A-C, right rows).  
   To investigate whether elafin affects the 
phosphorylation of IκBα, cells were 
treated with or without the proteasome 
inhibitor ALLN (100 µg/ml for 30 mins), 
used to stabilize the labile phosphorylated 
IκBα. The U937s were incubated in 
medium alone, medium with ALLN, 
stimulated with LPS in the presence of 
ALLN, or preincubated with ALLN and 
then elafin followed by stimulation with 
LPS.  Phosphorylation of IκBα was 
observed in all samples treated with 
ALLN (Fig. 5A, lanes 3-8), though only 
weakly so in the samples not also treated 
with LPS (Fig. 5A, lanes 3-4). The 
increased phosphorylation of IκBα seen in 
the samples pretreated with elafin (Fig. 
5A, lanes 7-8) was similar to that observed 
in the samples treated with ALLN and 
LPS alone (Fig. 5A, lanes 5-6). 
   Because the NF-κB regulatory proteins 
IRAK, IκBα and IκBβ undergo 
ubiquitination in response to stimuli such 
as LPS, and because elafin did not appear 
to prevent the LPS-induced 
phosphorylation of IκBα, we assessed the 
possible effect of elafin on ubiquitin. 
U937 cells were incubated with medium 
alone, or stimulated with LPS with or 
without preincubation with elafin and 
cytoplasmic lysates were obtained. LPS-
induced polyubiquination appeared to 
increase in the prior presence of elafin 
(Fig. 5B, right lanes) compared to when 
stimulated with LPS alone (Fig. 5B, left 
lanes), as assessed by Western blot 
analysis.  
20 S proteasome activity assay data the 
effect of elafin on peptidase activity 
associated with the 20 S proteasome was 
determined. Elafin was found not to affect 
any of the peptidase activities assessed 
(Fig 5C). 
 
 
DISCUSSION 
Elafin inhibits LPS-induced production of 
MCP-1 in the U937 monocytic cell line by 
preventing the LPS-induced activation of 
AP-1 and NF-κB.  This anti-inflammatory 
effect appears to be dependent upon an 
effect of elafin on the ubiquitin-
proteasome pathway.  
 
   LPS activates the transcription factors 
AP-1 and NF-κB via a process that 
initially involves binding of LPS to the 
cell membrane proteins, TLR4 and MD-2, 
which is facilitated by CD14 (22). Signal 
can then be transduced via a MyD88-
dependent pathway involving IRAK and 
TNF-receptor associated factor (TRAF)-6 
resulting in activation of the MAPK 
kinase, TAK1 (23,24). From this point, 
TAK-1 acts as a common activator of NF-
κB and AP-1 pathways. The subsequent 
phoshorylation of a group of inhibitory-
binding proteins kappa B (IκB) allows 
them to be ubiquitinated and degraded, 
which allows NF-κB to translocate into 
the nucleus (25). In the AP-1 pathway, 
JNK phosphorylation leads to activation of 
a number of proteins including ATF-2 and 
c-jun, subunits of AP-1 (26).  
 
    In our study, elafin prevented the LPS-
induced phosphorylation of JNK and the 
subsequent phosphorylation of the AP-1 
subunits, ATF2 and c-jun. Although the 
kinase p38 is also responsible for the 
phosphorylation and activation of AFT2, 
elafin had no effect on the LPS-induced 
phosphorylation of p38. In addition, elafin 
also prevented the LPS-induced 
degradation of the NF-κB regulatory 
proteins, IRAK, IκBα and IκBβ. These 
proteins are regulated by phosphorylation, 
ubiquitination and proteasomal 
degradation (25). While elafin appeared to 
have no effect on LPS-induced 
phosphorylation of IκBα, we found that 
elafin appears to delay ubiquitination of 
proteins in response to LPS, which 
corresponded to the inhibition of LPS-
induced IRAK, IκBα and IκBβ 
degradation in the presence of elafin. 
Upon activation by LPS, IRAK associates 
with TRAF6, and the latter is required for 
activation of germinal center kinase 
(GCK), by transiently stabilizing the 
ubiquitinated GCK polypeptide. GCK then 
participates in the optimal activation of 
JNK (27). It may be that elafin somehow 
perturbs the TRAF6-dependent 
stabilization of GCK by interfering with 
the ubiquitin-proteasome machinery that 
normally regulates GCK. This would 
account for our observed inhibitory effect 
of elafin on JNK as opposed to p38 
phosphorylation. 
 
   Taken together, these observations 
suggest that elafin’s inhibition of LPS-
induced AP-1 and NF-κB activity is due to 
an inhibitory effect of elafin on the 
ubiquitin-proteasome pathway. We have 
previously shown similar effects of SLPI 
on LPS and LTA-induced IRAK, IκBα 
and IκBβ degradation (8,9). We have 
recently demonstrated that SLPI can enter 
monocytes thus suggesting a direct effect 
of SLPI on the ubiqutin-proteasome 
pathway (28). Another antimicrobial 
peptide, PR-39, has been shown to inhibit 
TNF-induced NF-κB activation by binding 
directly to subunits of the proteasome 
(29). Therefore, it seems likely that the 
anti-inflammatory activity of SLPI and 
elafin are due, in part, to their ability to 
enter cells and act at some point on the 
ubiquitin-proteasome pathway resulting in 
delayed turnover of polyubiquinated 
proteins with repercussions for activation 
of the NF-kB and AP-1 pathways. 
 
   In conclusion, the evidence presented in 
this study shows that elafin inhibits LPS-
induced AP-1 and NF-κB activation 
through an effect on the ubiquitin-
proteasome pathway. Due to it’s selective 
expression at mucosal surfaces, as well as 
in alveolar macrophages, monocytes and 
neutrophils, elafin’s ability to inhibit LPS 
signalling may be important in disease 
states such as cystic fibrosis, pneumonia 
and acute respiratory distress syndrome. 
The inhibition of two key inflammatory 
pathways confirms the importance of 
elafin as a mediator of the innate immune 
response.
 
 
 
 
 
REFERENCES 
 
1. McElvaney, N. G., Taggart, C.C. (2005) Antiproteases. In: Barnes, P. (ed). 
Chronic Obstructive Pulmonary Disease Cellular and Molecular Mechanisms, 
Taylor Francis, Boca Raton, FL, USA 
2. Schalkwijk, J., Wiedow, O., and Hirose, S. (1999) Biochem J 340 (Pt 3), 569-
577 
3. Guyot, N., Zani, M. L., Berger, P., Dallet-Choisy, S., and Moreau, T. (2005) 
Biol Chem 386(4), 391-399 
4. Bingle, L., Tetley, T. D., and Bingle, C. D. (2001) Am J Respir Cell Mol Biol 
25(1), 84-91 
5. Zhang, M., Zou, Z., Maass, N., and Sager, R. (1995) Cancer Res 55(12), 
2537-2541 
6. Simpson, A. J., Maxwell, A. I., Govan, J. R., Haslett, C., and Sallenave, J. M. 
(1999) FEBS Lett 452(3), 309-313 
7. Vachon, E., Bourbonnais, Y., Bingle, C. D., Rowe, S. J., Janelle, M. F., and 
Tremblay, G. M. (2002) Biol Chem 383(7-8), 1249-1256 
8. Taggart, C. C., Greene, C. M., McElvaney, N. G., and O'Neill, S. (2002) J 
Biol Chem 277(37), 33648-33653 
9. Greene, C. M., McElvaney, N. G., O'Neill, S. J., and Taggart, C. C. (2004) 
Infect Immun 72(6), 3684-3687 
10. Sozzani, S., Locati, M., Zhou, D., Rieppi, M., Luini, W., Lamorte, G., 
Bianchi, G., Polentarutti, N., Allavena, P., and Mantovani, A. (1995) J Leukoc 
Biol 57(5), 788-794 
11. Rollins, B. J. (1996) Mol Med Today 2(5), 198-204 
12. Kurihara, T., Warr, G., Loy, J., and Bravo, R. (1997) J Exp Med 186(10), 
1757-1762 
13. Boring, L., Gosling, J., Chensue, S. W., Kunkel, S. L., Farese, R. V., Jr., 
Broxmeyer, H. E., and Charo, I. F. (1997) J Clin Invest 100(10), 2552-2561 
14. Kuziel, W. A., Morgan, S. J., Dawson, T. C., Griffin, S., Smithies, O., Ley, K., 
and Maeda, N. (1997) Proc Natl Acad Sci U S A 94(22), 12053-12058 
15. Hall, D. J., Bates, M. E., Guar, L., Cronan, M., Korpi, N., and Bertics, P. J. 
(2005) J Immunol 174(12), 8056-8063 
16. Hanazawa, S., Takeshita, A., Amano, S., Semba, T., Nirazuka, T., Katoh, H., 
and Kitano, S. (1993) J Biol Chem 268(13), 9526-9532 
17. Waetzig, V., Czeloth, K., Hidding, U., Mielke, K., Kanzow, M., Brecht, S., 
Goetz, M., Lucius, R., Herdegen, T., and Hanisch, U. K. (2005) Glia 50(3), 
235-246 
18. Martin, T., Cardarelli, P. M., Parry, G. C., Felts, K. A., and Cobb, R. R. (1997) 
Eur J Immunol 27(5), 1091-1097 
19. Arndt, P. G., Suzuki, N., Avdi, N. J., Malcolm, K. C., and Worthen, G. S. 
(2004) J Biol Chem 279(12), 10883-10891 
20. Bradford, M. M. (1976) Anal Biochem 72, 248-254 
21. Mullally, J. E., Moos, P. J., Edes, K., and Fitzpatrick, F. A. (2001) J Biol 
Chem 276(32), 30366-30373 
22. Guha, M., and Mackman, N. (2001) Cell Signal 13(2), 85-94 
23. Lomaga, M. A., Yeh, W. C., Sarosi, I., Duncan, G. S., Furlonger, C., Ho, A., 
Morony, S., Capparelli, C., Van, G., Kaufman, S., van der Heiden, A., Itie, A., 
Wakeham, A., Khoo, W., Sasaki, T., Cao, Z., Penninger, J. M., Paige, C. J., 
Lacey, D. L., Dunstan, C. R., Boyle, W. J., Goeddel, D. V., and Mak, T. W. 
(1999) Genes Dev 13(8), 1015-1024 
24. Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, 
M., Nakanishi, K., and Akira, S. (1998) Immunity 9(1), 143-150 
25. Palsson-McDermott, E. M., and O'Neill, L. A. (2004) Immunology 113(2), 
153-162 
26. Davis, R. J. (2000) Cell 103(2), 239-252 
27. Zhong, J., and Kyriakis, J. M. (2004) Mol Cell Biol 24(20), 9165-9175 
28. Taggart, C. C., Cryan, S. A., Weldon, S., Gibbons, A., Greene, C. M., Kelly, 
E., Low, T. B., O'Neill S, J., and McElvaney, N. G. (2005) J Exp Med 
202(12), 1659-1668 
29. Gao, Y., Lecker, S., Post, M. J., Hietaranta, A. J., Li, J., Volk, R., Li, M., Sato, 
K., Saluja, A. K., Steer, M. L., Goldberg, A. L., and Simons, M. (2000) J Clin 
Invest 106(3), 439-448 
 
 
 
FIGURE LEGENDS 
Fig. 1. Elafin inhibits LPS-induced MCP-1 production and AP-1 activation in U937 cells. A, 
Effect of elafin on MCP-1 production. U937s were cultured (1 x 106/ml) in medium alone, 
with LPS (0.1µg/ml), or pre-incubated with elafin (10µg/ml) for 1h at 37 °C followed by 
incubation with LPS (0.1µg/ml) for 24h. MCP-1 ELISA represents results from three 
experiments. Elafin down-regulation of LPS-induced AP-1 (B) and NF-κB (C) activation. 
Nuclear extracts were prepared from U937s cultured in medium alone, with LPS (2µg/ml) or 
pre-incubated with elafin (10µg/ml) followed by activation with LPS (2µg/ml) over a time 
course shown in minutes. Reaction mixtures containing 5µg of protein and 0.5µL of biotin 
end-labeled oligonucleotide containing either the AP-1 or NF-κB consensus sequences were 
resolved by electrophoresis on a 6% polyacrylamide gel. Each EMSA represents results from 
three experiments. Con, control. 
Fig. 2. Elafin prevents LPS-induced phosphorylation of ATF2 and c-jun. A, Effect of elafin 
on ATF2 phosphorylation. Nuclear lysates from U937s cultured (2 x 106/ml) in medium 
alone, with LPS (2µg/ml) or pre-incubated with elafin (10µg/ml) followed by LPS (2µg/ml) 
over the time courses shown in minutes, were electrophoresed on a 10% SDS-PAGE and 
probed by Western blot for phosphorylated and total ATF2 antibody, A, and phosphorylated 
and total c-jun, B. Results shown are representative of three separate experiments. Con, 
control. Phospho, phosphorylated. 
Fig. 3. Elafin has no effect on p38 phosphorylation, but inhibits JNK phosphorylation. U937s 
were cultured (1 x 106/ml) in medium alone, with LPS (2µg/ml) or pre-incubated with elafin 
(10µg/ml) followed by LPS (2µg/ml) over the time courses indicated, and cytoplasmic, A,  
and nuclear fractions, B, were subjected to Western analysis for phosphorylated and total p38. 
Cytoplasmic and nuclear  fractions were also analysed for phosphorylated JNK, C, and Lamin 
B1, D, the latter as a loading control. Results shown are representative of three separate 
experiments. Con, control. Phospho, phosphorylated. 
Fig. 4. Elafin prevents LPS-induced degradation of IκBα, IκBβ and IRAK. A, U937s were 
cultured (2 x 106/ml) in medium alone, with LPS (2µg/ml) or pre-incubated with elafin 
(10µg/ml) followed by activation with LPS (2µg/ml) over the time courses shown in minutes, 
and cytoplasmic fractions were subjected to Western analysis for IκBα, A, IκBβ, B, and 
IRAK, C. Results shown represents results of three experiments. Con, control. 
Fig. 5. Elafin has no effect on LPS-induced phosphorylation of IκBα, or on specified 20 S 
peptidase activities, but results in increased  ubiquitination. U937s were cultured (2 x 106/ml) 
in medium alone, the remainder were cultured with the proteasome inhibitor ALLN (1µL/ml), 
either alone and with LPS (2µg/ml) or pre-incubated with elafin (10µg/ml, 1h) followed by 
LPS (2µg/ml, 30 min).  Cytoplasmic lysates were electrophoresed on a 10% SDS-PAGE and 
probed by Western blot for phosphorylated IκBα, A. Cytoplasmic extracts from cells 
treated in medium alone, with LPS, or preincubated with elafin were assayed for 20 S 
peptidase activity, i.e. for chymotrypsin-like activity using Suc-LLVY-AMC, 
peptidylglutamyl peptide hydrolyzing activity using Z-Leu-Leu-Glu-AMC, and for trypsin- 
like activity using Z-Ala-Arg-Arg-AMC. Extracts were incubated in buffer (25mM HEPES, 5 
mM EDTA, 0.1% CHAPS, 5mM ATP, pH 7.5 with 2 mM DTT) for 30 min at 37 °C, and 
fluorescence was determined by excitation at 355nm and emission at 460nm, B. Cells were 
also cultured (2 x 106/ml) in medium alone, with LPS (2µg/ml) or pre-incubated with elafin 
followed by activation with LPS (2µg/ml) over the time courses shown in hours, and 
cytoplasmic fractions were subjected to Western analysis for ubiquitin, C  Results shown are 
representative of three separate experiments. Con, control. Phospho, phosphorylated, FU, 
fluorescence units 
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